Depomed


Nucynta Transaction Transforms Depomed Into A Leading Pain Company, Says Roth Capital

In a research report published Friday, Roth Capital analyst Scott Henry upgraded shares of Depomed (NASDAQ:DEPO) from a Neutral to a Buy rating and …

Depomed: We Remain Neutral On The Name But With A Positive Bias, Says Roth Capital

Yesterday, Roth Capital analyst Scott Henry issued a note in which he reiterated a Neutral rating on Depomed Inc. (DEPO) with a $13.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts